Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Calcium Pantothenate→

Calcium Pantothenate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
137-08-6
Molecular formula
C18H32CaN2O10
Molecular weight
476.5 g/mol
Drug class
Calcium salt of pantothenic acid (vitamin B5)nutritional vitamin
Mechanism of action
Provides pantothenate, a precursor for coenzyme A and acyl carrier protein, required for fatty-acid synthesis and oxidation and numerous acyl-transfer reactions in intermediary metabolism. Calcium is a counter-ion and nutrient contributor.
Indications / reported uses
  • Prevention and treatment of pantothenic acid deficiency and nutritional supplementation; no general therapeutic indication for unrelated conditions should be inferred from pantothenate biochemical function

Sources: NIH Office of Dietary Supplements — Pantothenic acid fact sheet · PubChem — Calcium pantothenate · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Calcium Pantothenate Environmental Risk Assessment (ERA) (the Calcium Pantothenate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.